Aditum Bio — Full Portfolio
7 tracked investments · listed companies and verified rows first
Co-investorsKleiner PerkinsMassChallenge MexicoMicron Ventures
Coastline Bio is a biopharmaceutical company developing novel medicines for immunological skin diseases, with an initial focus on atopic dermatitis.
BiotechHealthtechMedical DevicesOakland, US
BiotechOakland, US
Christian Klee(Executive Officer)Joshua Gertsman(Director)Paul Johnson(Executive Officer, Director)Ricardo Dolmetsch(Executive Officer, Director)Julie Shah(Executive Officer)Joseph Jimenez(Director)
Board seatJoseph JimenezJoshua Gertsman· per SEC Form D · $77M raise · filed Nov 2025
Co-investors8VC
Via Nova develops antiviral therapies targeting acute and subacute viral infections, including respiratory, gastrointestinal, and neurological infections.
BiotechDigital HealthMedical DevicesOakland, US
Donald Ganem(Executive Officer, Director)Benjamine Liu(Director)Ilan Zipkin(Director)
Board seatJoseph Jimenez· per SEC Form D
Co-investorsPMV
Celexor Bio develops monoclonal antibody therapeutics targeting plasmacytoid dendritic cells to treat severe autoimmune and inflammatory disorders by interrupting the inflammatory cascade at its source.
BiotechDigital HealthMedical DevicesOakland, US
Kalexo Bio develops dual-targeting siRNA therapeutics for cardiovascular disease, with a focus on lipid management and atherosclerotic disease prevention.
BiotechDigital HealthMedical Devices
Oblenio Bio develops LBL-051, a tri-specific T-cell engager therapy targeting BCMA, CD19, and CD3 for treating refractory autoimmune diseases through B-cell and plasma cell depletion.
BiotechHealthtechMedical DevicesLexington, US
Samantha Truex(Chief Executive Officer)in
Co-investorsGV (Google Ventures)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.